Anbogen Therapeutics, Inc. has been awarded the 21st National Innovation Award for its innovative lead asset ABT-301 combined with immune checkpoint inhibitors. This recognition highlights Anbogen's potential in cancer immunotherapy, specifically for microsatellite stable (MSS) metastatic colorectal cancer patients with limited treatment options.

The National Innovation Award, established in 2003 by the Institute for Biotechnology and Medicine Industry (IBMI), recognizes research achievements with innovative breakthroughs and industrial application value in the biomedical and health sectors. In 2024, Anbogen stood out with its cutting-edge research on cancer treatment.

ABT-301, in combination with immune checkpoint inhibitors (ICI), brings new hope to MSS metastatic colorectal cancer patients. Previous ICIs have made significant progress in cancer treatment, but their cure rate remains below 20%. ABT-301's unique mechanism of action effectively regulates the tumor microenvironment, enhancing the efficacy of immunotherapy. This innovative combination therapy offers new treatment opportunities for patients with limited effective options.

Anbogen has demonstrated our R&D capabilities, successfully translating laboratory results into therapies with clinical application potential. The research embodies the "Created in Taiwan (CIT)" concept, combining local talents with global resources to promote Taiwan's biotech innovation to the world.

Anbogen’s CEO Tsu-An Hsu stated, "Winning the National Innovation Award is a high recognition of our team's innovative efforts and research vision. The development of ABT-301 combined with immune checkpoint inhibitors demonstrates our commitment to advancing cancer treatment. We will continue to push forward with this research and seek future clinical trial opportunities to provide more options for patients." This award not only acknowledges Anbogen Therapeutics' innovative research and development but also highlights our dedication to enhancing the quality of life and extending the survival of cancer patients.